A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Sponsor
Takeda
Study ID
NCT06323356
Phase
PHASE3
Status
Active Not Recruiting

Conditions

  • Erythrodermic Psoriasis
  • Generalized Pustular Psoriasis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • TAK-279 — DRUG
    Specified drug on specified days.

Study Details

The main aim of this study is to check if TAK-279 improves symptoms of With Generalized Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP) and side effect from the study treatment or TAK-279. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 61 weeks including 52 weeks of study treatment. During the study, participants will visit their study clinic for multiple times.

Key Dates

Start date
Mar 19, 2024
Status verified
Nov 2025
Primary completion
Oct 15, 2025
Completion
Jul 22, 2026

Study Design

Enrollment
18 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: TAK-279 for Generalized Pustular Psoriasis
    Participants with generalized pustular psoriasis will receive TAK-279 from Day 1 up to Week 52.
  • Experimental: TAK-279 for Erythrodermic Psoriasis
    Participants with erythrodermic psoriasis will receive TAK-279 from Day 1 up to Week 52.

Primary Outcome Measure

Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Week 16 [ Time Frame: Baseline, Week 16 ]

Related Studies